CATHERINE SERMET

Deputy Director

Doctor in medicine

33 (0)1 53 93 43 37

sermet@irdes.fr

Assistant: Catherine Banchereau

33 (0)1 53 93 43 23

banchereau@irdes.fr

RESEARCH ACTIVITIES

Research interest

• Prescription drugs, medical goods
• Health status, risk factors
• Inequalities in health and health care use

Current interest

• Impact of drug delisting
• Price determinants of me-too drugs
• Diffusion of pharmaceutical innovation
• Drug prescription efficiency
• Health care use of individuals with disabilities

Other activities

• Member of the French High Council for Public Health (HCSP) Commission on Long Standing Illness
• Member of the Commitee ‘Economic Evaluation and Public Health’, French National Authority for Health (HAS)

LATEST ENGLISH PUBLICATIONS

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.
Malmström R.E., Godman B.B., Diogene E., Baumgärtel C., Bennie M., Bishop I., Brzezinska A., Bucsics A., Campbell S., Ferrario A., Finlayson A.E., Fürst J., Garuoliene K., Gomes M., Gutiérrez-Ibarluzea I., Haycox A., Hviding K., Herholz H., Hoffmann M., Jan S., Jones J., Joppi R., Kalaba M., Kvalheim C., Laius O., Langner I., Lonsdale J., Lööv S.Å., Malinowska K., McCullagh L., Paterson K., Markovic-Pekovic V., Martin A., Piessnegger J., Selke G., Sermet C., Simoens S., Tulunay C., Tomek D., Vončina L., Vlahovic-Palcevski V., Wale J., Wilcock M., Wladysiuk M., van Woerkom M., Zara C., Gustafsson L.L., Frontiers in pharmacology, vol 4, article 39, 2013/05, 1-31.
On Frontiers site

Multilevel Analysis of the Influence of Patients' and General Practitioners' Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France.
Pichetti S., Sermet C., Godman B., Campbell S.M., Gustafsson L.L., Applied Health Economics and Health Policy, en ligne, 2013/04, 1-14.
On Springer Link site

Essential to increase the use of generics in Europe to maintain comprehensive health care ?
Godman B., Bennie M., Baumgärtel C., Sovic-Brkicic L., Burkhardt T., Fürst J., Garuoliene K., Gomes M., Markovic-Pekovic V., Martin A., Sermet C., Skiold P., Van Woerkom M., Voncina L., Gustafsson L.L., Farmeconomia. Health economics and therapeutic pathways, 2012, vol 13, Suppl n°3S, 5-20.
On Farmeconomia site

How to Explain Price Gaps between Me-too Drugs?
A 2001-2009 Panel-data Analysis
Bergua L. (CHU de Rouen), Cartier T. (Université Paris Diderot, Sorbonne Paris Cité, Irdes), Célant N. (Irdes), Pichetti S. (Irdes), Sermet C. (Irdes), Sorasith C. (Irdes)
Issues in Health Economics (Questions d'économie de la santé) n° 178. 2012/07-08.

European payer initiatives to reduce prescribing costs through use of generics.
Godman B., Wettermark B., Sermet C. et al., GaBi Journal : Generics and Biosimilars Initiative Journal, vol. 1, issue 1, 2012, 22-27.
On GaBi Journal site

What lessons can be learned from the launch of generic clopidogrel?
Baumgärtel C., Godman B., Malmstrom R.E., Andersen M., Abuelkhair M., Abdu S., Bennie M., Bishop I., Burkhardt T., Fahmy S., Furst J., Garuoliene K., Herholz H., Kalaba M., Koskinen H., Laius O., Lonsdale J., Malinowska K., Ringerud A.M., Schwabe U., Sermet C., Skiold P., Teixeira I., van Woerkom M., Vitry A., Vončina L., Zara C., Gustafsson L.L., Generics and Biosimilars Initiative Journal (GaBI Journal). vol 1, n°2, 2012, 58-68.
On GaBi Journal site

Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach.
Godman B., Abuelkhair M., Vitry A., Abdu S., Bennie M., Bishop I., Fahmy S., Garuoliene K., Herholz H., Martin A., Malmstrom R.E., Jan S., Schwabe U., Sermet C., Skiold P., Voncina L., Gustaffson L.L., Generics and Biosimilars Initiative Journal (GaBI Journal). vol 1, n°2, 2012, 69-83.
On GaBi Journal site

Analysis of the Impact of Drug Delisting in France between 2002 and 2011
Pichetti S., Sermet C.
Issues in Health Economics (Questions d'économie de la santé) n° 167. 2011/07-08

Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on presciption rates: A time-series analysis for France 1998-2010.
Pichetti S., Sorasith C., Sermet C., Health Policy, vol.102, issues 2-3, 2011/10, 159-169.

The Health of Older Workers in Europe: Results of SHARE 2006
Lenormand M.-C., Sermet C., Sirven N.
Issues in Health Economics (Questions d'économie de la santé) n° 160. 2010/12

Policies to enhance prescribing efficiency in Europe: findings and future implications.
Godman B., Shrank W., Andersen M., Berg C., Bishop I., Burkhardt T., Garuoliene K., Herholz H., Joppi R., Kalaba M., Laius O., Lonsdale J., Malmström R.E., Martikainen J.E., Samaluk V., Sermet C., Schwabe U., Teixeira I., Tilson L., Tulunay F.C., Vlahovic-Palcevski V., Wendykowska K., Wettermark B., Zara C., Gustafsson L.L., Frontiers in pharmacology, vol 1, article 141, 2011/01, 1-16.
On Frontiers site

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization : changes seen and global implications.
Godman B., Shrank W., Andersen M., Berg C., Bishop I., Burkhardt T., Garuoliene K., Herholz H., Joppi R., Kalaba M., Laius O., McGinn D., Samaluk V., Sermet C., Schwabe U., Teixeira I., Tilson L., Tulunay F.C., Vlahović-Palčevski V., Wendykowska K., Wettermark B., Zara C., Gustafsson L.L., Expert Review of Pharmacoeconomics & Outcomes Research, vol 10, n°6, 2010/12, 707-722.
On Expert reviews site

Use of Generics - A Critical Cost Containment Measure for All Healthcare Professionals in Europe ?
Godman B., Shrank W., Wettermark B., Andersen M., Bishop I., Burkhardt T., Garuolienè K., Kalaba M., Laius O., Joppi R., Sermet C., Schwabe U., Teixeira I., Cankat Tulunay F., Wendykowska K., Zara C., L. Gustafsson L., Pharmaceuticals, vol 3, n°2, 2010, 2470-2494.
On MDPI site

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
Adamski J., Godman B., Ofierska-Sujkowska G., Osinska B., Herholzl H., Wendykowska K., Laius O., Jan S., Sermet C., Zara C., Kalaba M., Gustafsson R., Garuoliene K., Haycox A., Garattini S., Gustafsson L.L., BMC Health Services Research, vol 10, n°153, 1-29, 2010/06.
On Biomedcentral site

Ongoing pharmaceutical reforms in France : Implications for Key Stakeholder Groups, Sermet C., Andrieu V., Godman B., Van Ganse E., Haycox A ., Reynier J.P., Applied Health Economics and Health Policy, vol 8, n°1, 2010, 7-24
Abstract

Immigrants’ Access to Ambulatory Care in France
Dourgnon P., Jusot F., Sermet C., Silva J., 2009/09.
Questions d'économie de la santé n° 146

Self-assessed health of individuals aged 55 and over in France and Québec: differences and similarities
Camirand J. (ISQ), Sermet C. (Irdes) , Dumitru V. (ISQ), Guillaume S. (Irdes), 2009/05
Questions d'économie de la santé n° 142

Evolution 1998-2002 of the antidepressant consumption in France, Germany and the United Kingdom
Grandfils N., Sermet C.
Working paper n° 21, 2009/02

New obesity body mass index threshold for self-reported data. Dauphinot V., Wolff H., Naudin F., Gueguen R., Sermet C., Gaspoz J.M., Kossovsky M.P., Journal of Epidemiology and Community Health, 2009/02, vol 63, n°2, 128-132.
Abstract

Self assessed health of immigrants in France - Analysis of the 2002-03 decennial health survey
Dourgnon P., Jusot F., Sermet C., Silva J., 2008/07 (March 2009 for the English version)
Questions d'économie de la santé n° 133

Social heterogeneity in self-reported health status and measurement of inequalities in health
Tubeuf S., Jusot F., Devaux M., Sermet C.
Working paper n° 12, 2008/06

Delisting of mucolytics and expectorants: what is the impact on general practitioners’ prescribing?
Devaux M., Grandfils N., Sermet C., 2007/12
Questions d'économie de la santé n° 128

Job loss from poor health, smoking and obesity : a national prospective survey in France. Jusot F., Khlat M., Rochereau T., Sermet C., Journal of Epidemiology and Community Health, n°4, vol 62, 2008/04, 332-337.
Full text on the JECH's site

Bad health strongly increases the risk of becoming unemployed or inactive
Jusot F., Khlat M., Rochereau T., Sermet C. September 2007
Questions d'économie de la santé n° 125

What do we suffer from? Evaluation of declared diseases in France Decennial Health Survey, Insee 2002-2003.Allonier C., Guillaume S., Sermet C., 2007/06
Questions d'économie de la santé n° 123

Health working life expectancies at age 50 in Europe : a new indicator, Lièvre A., Jusot F., Barnay T., Sermet C., Brouard N., Robine J.M., Brieu M.A., Forette F., The Journal of Nutrition, Health & Aging, vol 11, n° 6, 2007
Full text on the JNHA site

Differences between reported and diagnosed morbidity The examples of obesity, arterial hypertension and hypercholesterolemia. Dauphinot V., Naudin F., Gueguen R.(CETAF), Perronnin M., Sermet C. (Irdes), 2006/11
Questions d'économie de la santé n° 114

Pharmaceutical policy in France : a mosaic of reforms.Grandfils N., Sermet C., Eurohealth, 2006, vol.12, n° 3, 15-17.
Full text on the LSE site

Expenditure on prevention and care by disease in France
Fénina A., Geffroy Y., Minc C., Renaud T., Sarlon E, Sermet C., 2009/07
Questions d'économie de la santé n° 111

The politics of drug reimbursement in England, France and Germany.
N'Guyen L., Or Z. , Paris V. , Sermet C. 2005/10
Questions d'économie de la santé n° 99

Are measures of health and economic activity comparable in european surveys?
Barnay T., Jusot F., Rochereau T., Sermet C. 2005/06
Questions d'économie de la santé n° 96

Comparability of health surveys in Europe : France, United Kingdom, Russia, Poland, Czech Republic, Germany, Greece, Italy, Spain and Sweden."Indicators of active life expectancy" - Project International Longevity Centre, Barnay T., Jusot F., Rochereau T., Sermet C., Irdes/ILC, 2005/02/28.
Report
Appendix

Drug delisting and reduced reimbursement
Naudin F., Sermet C., Health Policy Monitor, 2003
Full text on the International network health policy & reform's site

More information on the French Site